Clinical Trial Update: The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study is evaluating a triple regimen for newly diagnosed acute myeloid leukemia with FLT3 mutation. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: FLT3 Gene Mutation, AML | Phase 1, Phase 2 | Status: RECRUITING